Bioreductive drugs: selectivity towards hypoxic tissue

Bibliography

• COLEMAN CN: Hypoxia in tumours: a paradigm for the approach to biochemical and physiological heteroge-neity. J. Nail Cancer Inst. (1988) 80:310–317.
   PubMed Web of Science ®Google Scholar
• VAUPEL P, SCHLENGER K, KNOOP C, HOCKEL M: Oxygenation of human tumours: evaluation of tissue oxygen distribution in breast cancers by computer-ised 02 tension measurements. Cancer Res. (1991) 51:3316–3322.
   PubMed Web of Science ®Google Scholar
• •It is a comprehensive paper on the evaluation and measuring of hypoxia (in cancer) - the core of this paper
   Google Scholar
• SCHMEDTJE JF, JI YS: Hypoxia and molecular cardiovas-cular medicine. Trends Cardiovas. Med. (1998) 8:24–33.
   PubMedGoogle Scholar
• IKONOMIDOU C, TORSKI L: Excitotoxicity and neurodegenerative diseases. Curr. Opin. Neurol. (1995) 8:487–497.
   PubMed Web of Science ®Google Scholar
• WALSH DA: Angiogenesis and arthritis. Rheumatology (1999) 38:103–112.
   PubMed Web of Science ®Google Scholar
• WENGER RH, GASSMANN M: Oxygen and the hypoxia-inducible factor-1. J. Biol. Chem. (1997) 378:609–616.
   Google Scholar
• KENNEDY KA: Hypoxic cells as specific targets for chemotherapy. Anti-Cancer Drug Des. (1987) 2:181–194.
   PubMed Web of Science ®Google Scholar
• GATENBY RA, KESSLER HB, ROSENBLUM JS et al: Oxygen distribution in squamous cell carcinoma metastases and its relationship to the outcome of radiation therapy. Int. J. Rad. Oncol. Biol. Phys. (1988) 14:831–838.
   PubMed Web of Science ®Google Scholar
• HOCKEL M, SCHLENGER K, MITZE M, SCHAFFER U, VAUPEL P: Hypoxia and radiation response in human tumors. Semin. Rad. Oncol. (1996) 6:3–9.
   PubMed Web of Science ®Google Scholar
• WORKMAN P, STRATFORD IJ: The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metast. Rev. (1993) 12:73–82.
   PubMed Web of Science ®Google Scholar
• STRATFORD IJ, WORKMAN P: Bioreductive drugs into the next millennium. Anti-Cancer Drug Des. (1998) 13:519–528.
   PubMedGoogle Scholar
• •This is a most recent comprehensive review of the role of bioreductive drugs.
   Google Scholar
• DENNY WA, WILSON WR, HAY MP: Recent development in the design of bioreductive drugs. Br. J. Cancer. (1996) 4:S28–S31.
   Google Scholar
• ••Denny et al. are one of the major contributors to hypoxia-selective agents. This is a short but concise review on the development of bioreductive drugs.
   Google Scholar
• CRESTEIL T, JAISWAL AK: High levels of expression of the NAD(P)H-quinone oxidoreductase (NQ01) gene in tumour cells compared to normal cells of the same origin. Biochem. Pharmacol (1991) 42:1021–1027.
   PubMed Web of Science ®Google Scholar
• RAMPLING R, CRUICKSHANK G, LEWIS AD, FITZSIM-MONS SA, WORKMAN P: Direct measurement of p02 distribution and bioreductive enzymes in human malignant brain tumours. Int. J. Rad. Oncol. Biol. Phys. (1994) 29:427–431.
   PubMed Web of Science ®Google Scholar
• HODNICK WF, SARTORELLI A: Reductive activation ofmitomycin C by NADH-cytochrome bs reductase. Cancer Res. (1993) 53:4907–4921.
   PubMedGoogle Scholar
• PAN S, ANDREWS PA, GLOVER CJ, BACHUR NR: Reductive activation of mitomycin C and mitomycin C metabolites by NADPH-cytochrome P-450 reductase and xanthine oxidase. J. Biol. Chem. (1984) 259:959–966.
   PubMed Web of Science ®Google Scholar
• GUSTAFSON DL, PRISTOS CA: Bioactivation of mitomycin-C by xanthine dehydrogenase from EMT6 mouse mammary carcinoma tumors. J. Natl. Cancer Inst. (1992) 84:1180–1185.
   PubMed Web of Science ®Google Scholar
• WALTON MI, SMITH PJ, WORKMAN P: The role of NAD(P)H: quinone reductase (EC1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indolequinone anti-tumor agent E09. Cancer Commun. (1991) 3:199–206.
   Google Scholar
• BRIDGEWATER JA, SPRINGER CJ, KNOX RJ, MINTON NP, MICHAEL NP, COLLINS MK: Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectivity sensitive to killing by the prodrug CB 1954. Eur. J. Cancer (1995) 31A:2362–2370.
   PubMed Web of Science ®Google Scholar
• SMITSKAMP-WILMS E, HENDRIKS HR, PETERS GJ: Development, pharmacology, role of DT-diaphorase and prospects of the indolequinone E09. Gen. Pharmacol. (1996) 27:421–429.
   PubMedGoogle Scholar
• BUTLER J, SPANSWICK VJ, CUMMINGS J: The autoxida-tion of the reduced forms of E09. Free Rad. Res. (1996) 15:141–148.
   Google Scholar
• CARTER SK, CROOKE ST: Mitomycin C. In: Current Status and New Developments. Academic Press, New York, USA (1979).
   Google Scholar
• FRACASSO PM, SARTORELLI AC: Cytotoxicity and DNA lesions produced by mitomycin C and porfirmycin in hypoxic and aerobic EMT6 and chinese hamster ovary cells. Cancer Res. (1986) 46:3939–3944.
   PubMed Web of Science ®Google Scholar
• HENDRIKS HR, PIZAO PE, BERGER DP et al.: E09 - A novelbioreductive indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. Eur. J. Cancer (1993) 29A:897–906.
   PubMed Web of Science ®Google Scholar
• •This paper discusses the role of E09 (lead indolequinone bioreductive drug) and its effects on solid tumour activity and toxicity.
   Google Scholar
• SHELLENS JHM, PLANTING AST, VAN ACKER BAC et al.: Phase land pharmacological study of the novel indole-quinone bioreductive alkylating cytotoxic drug E09. J. Natl. Cancer Inst. (1994) 86:906–912.
   Google Scholar
• DIRIX LY, TONNESEN F, CASSIDY J et al.: Phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC early clinical studies group. Eur. J. Cancer (1996) 32A:2019–2022.
   PubMed Web of Science ®Google Scholar
• PAVLIDIS N, HANAUSKE AR, GAMUCCI T et al: A random-ised Phase II study with two schedules of the novel indolequinone E09 in non-small-cell lung cancer: a study of the EORTC early clinical studies group (ECSG). Ann. Oncol (1996) 7:529–531.
   PubMed Web of Science ®Google Scholar
• COTTERILL AS, MOODY CJ, MORTIMER RJ et al.: Cyclopropamitosenes, novel bioreductive anticancer agents. Synthesis, electrochemistry, and biological activity of 7-substituted cyclopropylmitosenes and related compounds. J. Med. Chem. (1994) 37:3834–3843.
   Google Scholar
• NAYLOR MA, JAFFAR M, NOLAN J et al.: 2-Cyclopropyl indoloquinones and their analogues as bioreductively activated antitumour agents: structure-activity in vitro and efficacy in vivo. J. Med. Chem. (1997) 40:2335–2346.
   PubMed Web of Science ®Google Scholar
• JAFFAR M, NAYLOR MA, ROBERTSON N et al.: 5-Substituted analogues of 3-hydroxymethy1-5-aziridiny1-1-methyl-2-[1H-indole-4,7-dione] prop-2-en-1-ol and their regioisomers as hypoxia-selective agents: structure-cytotoxicity in vitro. Anti-Cancer Drug Des. (1998) 13:105–123.
   PubMedGoogle Scholar
• ROBERTSON N, STRATFORD IJ, HOULBROOK S, CARMICHAEL J, ADAMS GE: The sensitivity of human tumour cells to quinone bioreductive drugs: what role for DT-diaphorase? Biochem. Pharmacol. (1992) 44:409–412.
   Google Scholar
• ROBERTSON N, HAIGH A, ADAMS GE, STRATFORD IJ: Factors affecting sensitivity to E09 in rodent and human cells in vitro: DT-diaphorase activity and hypoxia. Eur. J. Cancer (1994) 30A:1013–1019.
   PubMed Web of Science ®Google Scholar
• BAILEY SM, SUGGET N, WALTON MI, WORKMAN P: Structure-activity relationships for DT-diaphorase reduction of hypoxic cell directed agents: indolequinones and diaziridinylbenzoquinones. Int. J. Rad. Oncol. Biol. Phys. (1992) 22:649–653.
   PubMed Web of Science ®Google Scholar
• PHILLIPS R.M: Bioreductive activation of a series of analogues of 5-aziridiny1-3-hydroxymethy1-1-methyl-2-[1H-indole-4,7-dione]prop-2-en-1-ol (E09) by human DT-diaphorase. Biochem. Pharmacol. (1996) 52:1711–1718.
   PubMed Web of Science ®Google Scholar
• O'NEILL P, JENKINS TC, STRATFORD IJ et al.: Mechanism of action of some bioreducible 2-nitroimidazoles: comparision of in vitro cytotoxicity and ability to induce DNA strand breakage. Anti-Cancer Drug Des. (1987) 1:271–280.
   Google Scholar
• MOORE JL, PATERSON ICM, DAWES PJDK, HENK JM: Misonidazole in patients receiving radical radiotherapy - pharmacokinetic effects of phentoin tumor response and neurotoxicity. Int. J. Oncol Phys. Biol. (1982) 8:361–364.
   PubMedGoogle Scholar
• JENKINS TC, NAYLOR MA, O'NEILL P et al.: Synthesis and evaluation of a-[[(2-haloethyDamino]methyl - 2-nitro-1H-imidazole-1-ethanol (RB-6145) as prodrugs of a- [(1-aziridinyOmethy1]-2-nitro-1H-imidazole-1--ethanol (RSU-1069) and its analogues which are radiosensitisers and bioreductively activated cytotoxins. J. Med. Chem. (1990) 33:2603–2610.
   Google Scholar
• PARKER RF, VINCENT PW, ELLIOT WL: Alkylating properties of nitro-imidazole radiosensitizers is required for induction of murine retinal degeneration. Vet. Pathol. (1996) 33:625.
   Google Scholar
• KNOX RJ, BOLAND MP, FRIEDLOS F, COLES B, SOUTHAM C, ROBERTS JJ: The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-y1)-2,4- dinitroben-zamide (CB1954) to 5-(aziridin-1-y1)- 4-hydroxyl amino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (Ed .6.99.2). Biochem. Pharmacol (1988) 37:4671–4677.
   PubMed Web of Science ®Google Scholar
• KNOX RJ, FRIEDLOS F, JARMAN M, ROBERTS JJ: A new cytotoxic DNA interstrand cross-linking agent, 5- (aziridin-1-y1)-4-hydroxylamino-2-nitrobenzamide is formed from 5-(aziridin-1-y0-2,4-dinitrobenzamide (CB1954) by a nitroreductase enzyme in Walker carcinoma cells. Biochem Pharmacol. (1998) 37:4661–4669.
   Google Scholar
• FRIEDLOS F, DENNY WA, PALMER BD, SPRINGER C: Mustard prodrugs for activation by Escherichia coli nitroreductase in gene-directed enzyme prodrug therapy. J. Med. Chem. (1997) 40:1270–1275.
   PubMed Web of Science ®Google Scholar
• WILSON WR, TERCEL M, ANDERSON RF, DENNY WA: Radiation-activated prodrugs as hypoxia-selective cytotoxins: model studies with nitroarylmethyl quaternary salts. Anti-Cancer Drug Des. (1998) 13:663–685.
   PubMedGoogle Scholar
• •Wilson/Denny et al. were/are the fore-runners of this class of compounds. Releasing cytotoxic species induced by radiation at the site of action is of paramount importance to selectivity.
   Google Scholar
• BROWN JM: SR 4233 (Tirapazamine): a new anticancer drug exploiting hypoxia in solid tumour. Br. J. Cancer. (1993) 67:1163–1170.
   PubMed Web of Science ®Google Scholar
• •References [43,44] give comprehensive biological data on TPZ. A bioreductive drug which has recently entered the clinic.
   Google Scholar
• BROWN JM, WANG LH: Tirapazamine; laboratory data relevant to clinical activity. Anti-Cancer Drug Des. (1998) 13:529–539.
   PubMedGoogle Scholar
• •See note for reference 43.
   Google Scholar
• PATTERSON AV, SAUNDERS MP, CHINJI EC, PATTERSON LH, STRATFORD IJ: Enzymology of tirapazamine metabolism: a review. Anti-Cancer Drug Des. (1998) 13:541–573.
   PubMedGoogle Scholar
• PATTERSON AV, SAUNDERS MP, CHINJE EC, TALBOT DC, HARRIS AL, STRATFORD IJ: Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (5114233) and RSU 1069. Br. J. Cancer (1997) 76:1338–1347.
   PubMed Web of Science ®Google Scholar
• DORIE MJ, BROWN JM: Tumor-specific, schedule dependant interaction between tirapazamine (5114233) and cisplatin. CancerRes. (1993) 53:4633–4636.
   Google Scholar
• TREAT J, JOHNSON E, LANGER C et al: Tirapazamine with cisplatin in patients with advanced non small-cell lung cancer. A phase II study. J. Clin. Oncol. (1998) 16:3524–3527.
   PubMed Web of Science ®Google Scholar
• ••This paper provides clinical data on TPZ. It emphasises theimportance of using bioreductive drugs in conjunction with other chemotherapeutic agents.
   Google Scholar
• SMITH PJ, BLUNT JN, DESNOYERS R, GILES Y, PATTERSON LH: DNA topoisomerase II-dependent cytotoxicity of alkylaminonthroquinones and their N-oxides. Cancer Chemother. Pharm. (1997) 39:455–461.
   PubMed Web of Science ®Google Scholar
• HODGKISS RJ: Use of 2-nitroimidazoles as bioreductive markers for tumour hypoxia. Anti-Cancer Drug Des. (1998) 13:687–702.
   PubMedGoogle Scholar
• •This is a comprehensive/up-to-date review on hypoxic markers.
   Google Scholar
• ABOAGYE EO, KELSON AB, TRACY M, WORKMAN P: Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl) -2- (2-nitro-1-imidazoly0 acetamide (SR 4554, CRC 94/17): a non-invasive diagnostic probe for the measurement of tumour hypoxia by resonance spectroscopy and imaging, and by positron emission tomography. Anti-Cancer Drug Des. (1998) 13:703–730.
   PubMedGoogle Scholar
• ••It is a comprehensive review on the reduction of nitro-containing compounds, and their uses as HSAs and delivery agents.
   Google Scholar
• SIIM BG, DENNY WA, WILSON WR: Nitro-reduction as an elcetronic switch for bioreductive drug activation. Oncol. Res. (1997) 9:357–369.
   PubMedGoogle Scholar
• EVERETT SA, NAYLOR MA, PATEL KB, STRATFORD MRL, WARDMAN P: Bioreductively-activated prodrugs for targeting hypoxic tissues: elimination of aspirin from 2-nitroimidazole derivatives. Bioorg. Med. Chem. Letts. (1999) 9:1267–1272.
   PubMedGoogle Scholar
• •Papers [53,54] give examples of the reductive activation of nitroimidazoles/indolequinones as hypoxia-selective delivery agents.
   Google Scholar
• JAFFAR M, EVERETT SA, NAYLOR M et al: Prodrugs for the hypoxic tissues: regiospecific elimination of aspirin from reduced indolequinones. Bioorg. Med. Chem. Letts. 9:113–118.
   Google Scholar
• •See note for reference 53.
   Google Scholar
• NAYLOR MA, SWANN E, EVERETT SA et al: Indolequi-none anti-tumor agents: reductive activation and elimination from (5-methoxy-4,7-dioxo-indo1-3-yOmethyl derivatives and hypoxia-selective cytotox-icity in vitro. J. Med. Chem. (1998) 41:2720–2731.
   PubMedGoogle Scholar
• JAFFAR M, NAYLOR MA, ROBERTSON N, STRATFORD IJ:Targeting hypoxia with a new generation of indolequi-none. Anti-Cancer Drug Des. (1998) 13:593–609.
   PubMedGoogle Scholar